<?xml version="1.0" encoding="UTF-8"?>
<results title="country">
 <result pre="Chugai Pharmaceutical Co, Ltd., Tokyo, Japan[5], VLP Therapeutics, Gaithersburg, Maryland," exact="United States" post="of America[6], Global Health Innovative Technology Fund, Tokyo, Japan[7],"/>
 <result pre="by camelids) that are currently in clinical trials in the" exact="United States." post="In addition, polyclonal antibodies have been approved in the"/>
 <result pre="is being tested in 2 small, open-label pilot studies in" exact="Senegal" post="(NCT03041766 and NCT03799510). A larger 300-participant trial in Uganda,"/>
 <result pre="explored as a therapeutic option. Antibody SIgN-3C, identified by the" exact="Singapore" post="Immunology Network, neutralized all 4 dengue serotypes and decreased"/>
</results>
